Mesoblast Wins First Mesenchymal Stromal Cell Therapy FDA Approval for GVHD
The approval concludes what has been a difficult regulatory path for Ryoncil, which suffered FDA rejections in 2020 and 2023.
Mesoblast Wins First Mesenchymal Stromal Cell Therapy FDA Approval for GVHD Read More »
